ASCO 2007: Leadership Summit on Hematologic Malignancies

Discussion among Hematologists/Oncologists

June 2007

Price $2500

Deliverable: Transcript with key findings

Study Description and Objectives

§    Survey choices for first-, second-, and third-line therapy for MM including the use of:

§    Lenalidomide (Celgene’s Revlimid®)

§    Bortezomib (Millenium’s Velcade®)

§    Thalidomide (Celgene’s Thalomid®)

§    Review specific considerations in the prescription of each of the above drugs including dosing, side effects, and reimbursement

§    Examine the latest data presented at ASCO including:

§    Lenalidomide (Revlimid®) + high vs. low-dose dexamethasone for the treatment of MM

§    Lenalidomide (Revlimid®) for the treatment of relapsed/refractory NHL

§    Lenalidomide (Revlimid®) for the treatment of CLL

§    Bortezomib (Velcade®) as maintenance therapy for MM

§    Discuss a potential role for lenalidomide (Revlimid®) in MDS

§    Explore new pharmaceutical agents under development to treat MM, NHL, CLL, and MDS

Companies and Products Mentioned in This Report

Inclusion Criteria

Hospitals Represented